Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Empyema [PDF]
, 2011 Candida empyema is a serious complication of disseminated candidiasis. However, little is known about the intrapleural pharmacokinetics of echinocandins. We report the penetration of anidulafungin into the pleural fluid of a patient with
A. John Barrett +11 more
core +1 more source
Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin [PDF]
, 2020 BACKGROUND: Case reports and pharmacokinetic data suggest off-label echinocandin dosing may be needed to reach adequate serum concentrations in obese patients. Few outcome studies exist evaluating this population.
Davis, Susan L +3 more
core +1 more source
An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America [PDF]
, 2014 Incidence and mortality of candidaemia/invasive candidiasis (C/IC) is relatively high in Latin America versus North America and Europe. To assess efficacy and safety of intravenous (IV) anidulafungin in Latin American adults with documented C/IC.
Nucci, Marcio +6 more
core +1 more source
The in vitro efficacy of Anidulafungin with and without Nikkomycin Z against C. auris isolates. [PDF]
This thesis investigates the in vitro antifungal efficacy of anidulafungin alone and in combination with nikkomycin Z against 15 Candida auris isolates representing four major genetic clades. Candida auris is a multidrug-resistant pathogen posing serious
Amano, Chiaki
core
Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata [PDF]
, 2012 The aim of this study was to compare the in vitro and in vivo activities of micafungin, caspofungin, and anidulafungin against Candida glabrata. The MICs against 28 clinical isolates showed that the overall susceptibilities to caspofungin and to ...
Orlando F. +8 more
core +1 more source
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies [PDF]
, 2017 Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have driven the need for data to support echinocandin clinical efficacy in such patients.
Marcio Nucci +20 more
core +1 more source
Clinical experience of Anidulafungin for the treatment of patients with documented Candidemia [PDF]
, 2010 Candida species are the most common causes of invasive fungal infections in humans, producing infections that range from mucocutaneous disorders to invasive disease that can involve any organ.
Ghezzi M. C. +7 more
core +1 more source
ClinicoEconomics and Outcomes Research, 2015 S Grau,1 JC Pozo,2 E Romá,2 M Salavert,3 JA Barrueta,4 C Peral,4 I Rodriguez,5 D Rubio-Rodríguez,6 C Rubio-Terrés6 1Hospital del Mar (IMIM), Barcelona, 2Hospital Universitario Reina Sofía, Córdoba, 3Hospital ...
Grau S +8 more
doaj
Dynamics of Anidulafungin use in a Tertiary Care Hospital [PDF]
Journal of Clinical and Diagnostic Research, 2014 Zeliha Kocak Tufan +4 more
doaj +1 more source
HaematologicaBackground In the allogeneic HSCT, the incidence of Invasive Fungal Disease is 7-9% with high rate of mortality. Although the antifungal prophylaxis is crucial, the role of anidulafungin is unknown.
A. Carobene +19 more
doaj